Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Antidepressant monotherapy

Trazodone with innovative galenics achieves rapid and significant response

    • Market & Medicine
    • Pharmacology and toxicology
    • Psychiatry and psychotherapy
    • RX
    • Studies
  • 3 minute read

The antidepressant monotherapy with trazodone achieves an effective response after only one week with a single daily dose starting at 150 mg. The multifunctional antidepressant mechanism of action of the serotonin antagonist and reuptake inhibitor (SARI) has no significant effects on body weight and libido.

The launch of Trittico® Uno is a milestone in antidepressant monotherapy with trazodone. Thanks to the new galenics, consisting of modified starch with high amylose content, this innovative technology allows easy dosing and controlled release over 24 hours. A single dose of up to 300 mg of trazodone per day results in stable plasma levels within the therapeutic range for 24 hours.

Trazodone is a triazolopyridine-derived antidepressant that acts via serotonin 2A and 2C (5HT2A/2C) receptor antagonism and via inhibition of serotonin reuptake. Since its introduction as an atypical antidepressant with unique pharmacological properties, trazodone has been shown to be equivalent to other drug classes in several comparative studies. Immediate-release trazodone is prescribed primarily as a hypnotic in doses of 50 to 200 mg. At these low doses, immediate-release formulations achieve plasma concentrations sufficient to exploit sedative effects as a result of 5HT2A and H1 receptor antagonism but are not sufficiently sustained to induce an antidepressant effect. To achieve an antidepressant effect, higher daily doses must be followed if they are to sufficiently inhibit 5HT2A and 5HT2C receptors and block the serotonin transporter [1].

Need for effective therapies

Natural history studies have shown that only one-third of patients with major depression achieve remission after a single course of antidepressant treatment. Even after one year of four consecutive treatments with different antidepressants, only about two-thirds of patients with depression achieved remission. Another major limitation associated with the use of antidepressants is their delayed onset of action. It usually takes 4 to 6 weeks for the full therapeutic effect to manifest. Therefore, faster-onset antidepressants with improved tolerability that are free of initial activating/anxiety effects are urgently needed to improve treatment. It was shown that the antidepressant efficacy of trazodone correlated significantly with its steady-state plasma levels. Therefore, formulations of trazodone with different release rates may show a different course of efficacy in the mid- and long-term treatment of a depressive episode. Trazodone is a once-daily antidepressant with rapid onset of action and efficacy in treating symptoms of anxiety and insomnia, while possibly avoiding weight gain, sexual dysfunction, and activating side effects [2].

Fast and significant response

Trittico® Uno shows a rapid and significant response after only one week [1,2]. This was demonstrated in a large-scale, placebo-controlled, double-blind clinical trial, as well as confirmed by a real-world study in a practice-based setting [1,3]. The good safety profile also speaks for itself: adverse drug reactions were mostly mild to moderate and transient.

Source: OM Pharma Suisse AG

 

Literature:

  1. Sheehan DV, et al: Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study. Psychiatry 2009; 6(5): 20-33.
  2. Albert U, Lamba P, Stahl SM: Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action. CNS Spectr. 2021; 26(3):232-242.
  3. Češková E, Šedová M, Kellnerová R, Starobová O: Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice. Pharmacology 2018; 102(3-4): 206-212.

 

InFo NEUROLOGY & PSYCHIATRY 2022; 20(4): 7.

Publikation
  • InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
  • Monotherapy
  • Trazodone
Previous Article
  • Local therapy in HCC

Interdisciplinary combination therapies on the rise

  • Congress Reports
  • Gastroenterology and Hepatology
  • Oncology
  • RX
  • Studies
View Post
Next Article
  • Influenza vaccination

High age – high dose!

  • Congress Reports
  • General Internal Medicine
  • Geriatrics
  • Infectiology
  • News
  • Prevention and health care
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
View Post
  • 3 min
  • Public Health

Outpatient care in Switzerland: situation report

    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
View Post
  • 5 min
  • Practice Management

Improved quality of care aims for satisfied patients

    • CME continuing education
    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
    • Studies
View Post
  • 30 min
  • Chemsex - MSM, sex, chrystal meth & co.

Medical and psychosocial perspectives

    • CME continuing education
    • General Internal Medicine
    • Infectiology
    • Pharmacology and toxicology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • RX
View Post
  • 3 min
  • Bladder cancer

Tuberculosis vaccination reduces recurrences

    • Congress Reports
    • Oncology
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
    • Urology
View Post
  • 4 min
  • Oral JAK-i in atopic dermatitis

Benefits and risks: What does the current data say?

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.